Overview

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Status:
Completed

Trial end date:
2001-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.

Phase:

Phase 2

Details

Lead Sponsor:

InterMune

Treatments:

Amphotericin B
Antifungal Agents
Fluconazole
Flucytosine
Hydroxyitraconazole
Interferon-gamma
Interferons
Itraconazole
Liposomal amphotericin B
Miconazole